Myriad Genetics, Inc.’s (MYGN) share price has entered into oversold territory with a stochastic value of 17.8110. The Zacks Consensus Estimate on the company’s earnings for year ending June 2013 increased by 4 cents over the past week to $1.58 per share. Myriad Genetics, Inc. is a Zacks Rank #1 (“Strong Buy”) company.
More From Zacks.com
- Investment & Company Information
- Myriad Genetics